Tin tức & Cập nhật

Biologics prolong remission duration in ulcerative colitis

Among patients with ulcerative colitis (UC), treatment with biologic agents may lead to longer remission durations, a recent study has found. However, biologics appear to have no effect on the risk of resection, particularly in moderate to severe active disease.

Multipathogen testing an essential part of Test-Target-Treat strategy for respiratory illnesses

At a recent webinar, experts discussed the paradigm shift in respiratory illnesses and treatment practices as the COVID-19 pandemic transitions to an endemic phase. The late Dr Mohan Ravuru, Physician Researcher and former Asia Pacific Medical Director, Abbott, Dr Johnny Sinon, Senior Emergency Physician from Makati Medical Center, Philippines, and Associate Professor Nuntra Suwantarat, Infectious Disease Specialist, from Chulabhorn International College of Medicine, Thammasat University, Thailand, delivered informative presentations and engaged the audience through a stimulating panel discussion.

Among the topics covered were the ‘immunity debt’ phenomenon leading to potential epidemics, challenges in the differential diagnosis of COVID-19 and influenza, and the importance of point-of-care, multipathogen testing as a part of the Test-Target-Treat strategy in respiratory diseases.

Food interrupts absorption of diazepam nasal spray

Food appears to affect the pharmacokinetics of diazepam dosed via nasal spray, with absorption being markedly decreased and delayed, according to an open-label crossover study.

Targeted naltrexone eases binge drinking among sexual/gender minority men

Targeted oral naltrexone results in a significant reduction in drinking outcomes among sexual and gender minority men (SGM) with mild to moderate alcohol use disorder (AUD) during treatment, reports a study. This beneficial effect persists up to 6 months post-treatment.

ALXN1840 generates rapid, sustained copper mobilization in Wilson disease

In individuals with Wilson disease (WD), a rare disease of copper metabolism, ALXN1840 led to significantly greater copper mobilization compared with standard of care (SoC), findings from a rater-blinded phase III study have shown.